Policy & Regulation
XNK Therapeutics announces presentation at DNB Nordic Healthcare Conference in Oslo
5 December 2023 -

XNK Therapeutics AB, a Sweden-based clinical stage immunotherapy company that is focused on bringing new and more effective treatments to cancer patients, announced on Monday that Johan Liwing, CEO, will make a presentation at the DNB Nordic Healthcare Conference in Oslo, Norway, on 14 December at 10:15am CET.

This presentation will be followed by a short Q&A session, moderated by a DNB analyst.

The company is developing autologous NK cell-based cell therapy with a proprietary technology platform and a pipeline spanning both hematological malignancies and solid tumour indications. Its most advanced product, evencaleucel, is in phase II studies in combination with the CD38 antibody isatuximab targeting multiple myeloma.